Chloroquine‐induced cardiomyopathy: a reversible cause of heart failure. (20th February 2018)

• Record Type: Journal Article
• Authors: Yogasundaram, Haran; Hung, Whitney; Paterson, Ian D.; Sergi, Consolato; Oudit, Gavin Y.
• Is Part Of: ESC heart failure. Volume 5:Number 3(2018)
• Page Start: 372
• Page End: 375
• Publication Date: 2018-02-20
• Subjects: Chloroquine -- Cardiomyopathy -- Heart failure -- Cardiac MRI; Heart failure -- Periodicals; 616.129005
• DOI: 10.1002/ehf2.12276
• Languages: English
• ISSNs: 2055-5822

Abstract

Abstract: Chloroquine (CQ) and hydroxychloroquine (HCQ) are anti‐rheumatic medications frequently used in the treatment of connective tissue disorders. We present the case of a 45‐year‐old woman with CQ‐induced cardiomyopathy leading to severe heart failure. Electrocardiographic abnormalities included bifascicular block, while structural disease consisted of severe biventricular and biatrial hypertrophy. Appropriate diagnosis via endomyocardial biopsy led to cessation of CQ and subsequent dramatic improvement in symptoms and structural heart disease. Cardiac toxicity is an under‐recognized adverse effect of CQ/HCQ leading to cardiomyopathy with concentric hypertrophy and conduction abnormalities, with the potential for significant morbidity and mortality. Predisposing factors for CQ/HCQ‐induced cardiomyopathy have been proposed. CQ/HCQ cardiomyopathy is a phenocopy of Fabry disease, and α‐galactosidase A polymorphism may account for some heterogeneity of disease presentation.